COMT
COMT encodes the enzyme that clears dopamine and other catecholamines from the synapse, particularly in the prefrontal cortex. The Val158Met variant (rs4680) — sometimes called the "warrior/worrier" SNP — changes enzyme activity roughly four-fold between genotypes. The biology is real; the popular-science framing is oversimplified.
The prefrontal cortex's dopamine janitor.
COMT methylates and inactivates catecholamine neurotransmitters: dopamine, epinephrine, and norepinephrine. In most of the brain, dopamine is cleared primarily by the dopamine transporter (DAT). But the prefrontal cortex has very low DAT expression, so it relies disproportionately on COMT to terminate dopamine signalling. This means COMT activity has an outsized effect on prefrontal dopamine tone — and therefore on the cognitive functions the prefrontal cortex supports: working memory, executive function, attention regulation, and stress response.
The Val158Met polymorphism substitutes valine for methionine at codon 158 of the membrane-bound COMT isoform. The methionine version is less thermostable; at body temperature its catalytic activity is roughly one-quarter that of the valine version. People with two Met alleles therefore clear prefrontal dopamine more slowly, while Val/Val individuals clear it more quickly.
This creates a real but modest tradeoff. Met carriers tend to perform slightly better on baseline working memory tasks (more available dopamine) but show worse performance under acute stress (dopamine overshoot in the prefrontal cortex disrupts the inverted-U relationship between dopamine and cognitive function). Val carriers show the opposite pattern. Effect sizes are small in healthy populations and easily overwhelmed by training, sleep, and context.
One SNP, several real consequences.
What the evidence supports — and what it doesn't.
ClinVar classifies the common COMT variants (rs4680 and friends) as risk factors with small effect sizes for several phenotypes, none of which rise to the level of a pathogenic disease variant. The most replicated associations are with subtle differences in prefrontal cognition and stress response, and with pain perception sensitivity.
Where the evidence is reasonably strong:
- Pain perception: the low-pain-sensitivity (LPS), average-pain-sensitivity (APS), and high-pain-sensitivity (HPS) haplotypes correlate with experimentally measured pain thresholds and with risk of temporomandibular disorder.
- Pharmacogenomics — entacapone and tolcapone: these COMT inhibitors are used as adjuncts to levodopa in Parkinson's disease. COMT genotype is one of several factors influencing dose response.
- Catecholamine-driven phenotypes: 22q11.2 deletion syndrome (which encompasses COMT) shows clear cognitive and psychiatric phenotypes, but those are driven by the deletion, not the Val158Met polymorphism.
Where the evidence is weak or non-replicated:
- Schizophrenia risk — early small studies showed associations that did not survive large GWAS.
- "Warrior vs worrier" personality typing — useful pedagogically, but the actual effect on real-world behaviour is small and heavily moderated by environment.
- Anxiety disorders — modest, inconsistent findings.
"Met/Met carriers are not destined to be anxious, and Val/Val carriers are not immune to stress. The variant shifts a probability distribution; it does not assign a fate."
Primary sources: ClinVar — COMT gene entries; Lachman et al., Pharmacogenetics 1996 (original Val158Met characterization); Diatchenko et al., Hum Mol Genet 2005 (pain haplotypes); OMIM 116790 — COMT.
Look up your rs4680 genotype.
The COMT Val158Met variant is universally included in consumer SNP arrays. In your raw data file, search for rs4680. You will see one of three genotypes:
Note: some platforms report on the opposite strand and will show C/T instead of G/A. The biology is the same — what matters is whether you carry the Val (high-activity) or Met (low-activity) version.